Related Experiment Video
Updated: May 5, 2026

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
Published on: October 25, 2013
Study of antimicrobial effects of vancomycin loaded PLGA nanoparticles against enterococcus clinical isolates
F Lotfipour1, S Abdollahi2, M Jelvehgari2
1Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Abstract:
Researchers have demonstrated that antimicrobial agents in nanoparticle (NP) forms have better activities. Vancomycin (VCM), as a glycopeptide antibiotic with antimicrobial activity against gram positive bacteria, is poorly absorbed from the intestinal tract. Enterococcus is a genus of bacteria that became resistant to a wide range of antibiotics in last decades, and cause severe infections in hospitalized patients. This paper describes preparation of VCM--loaded poly (lactic-co-glycolic acid) (PLGA) NPs and compares the antimicrobial effects with drug solution against clinical Enterococcus isolates. VCM-loaded PLGA NPs were fabricated by W1/O/W2 solvent evaporation method. The comparison of obtained Minimum Inhibitory Concentration (MIC) values showed a significant decrease in the antimicrobial effect of VCM -loaded NPs. Results also indicated that the potency of the NPs against VCM resistant isolates of Enterococcus was less than VCM susceptible isolates. The reduced antimicrobial effect of formulated NPs in invitro condition is perhaps related to the strong electrostatic linkage between hydrophilic drug (VCM) and hydrophobic polymer (PLGA) that lead to the slow release of the antibiotic from polymeric NPs.
Insights
Antimicrobial vancomycin (VCM) nanoparticles showed reduced effectiveness against Enterococcus bacteria compared to VCM solution. This suggests challenges in nanoparticle drug delivery for treating resistant infections.
Area of Science:
- Pharmacology
- Materials Science
- Microbiology
Background:
- Nanoparticle (NP) formulations enhance antimicrobial agent activity.
- Vancomycin (VCM) is a glycopeptide antibiotic effective against Gram-positive bacteria but poorly absorbed intestinally.
- Enterococcus species are increasingly resistant to antibiotics and cause severe hospital-acquired infections.
Purpose of the Study:
- To prepare vancomycin-loaded poly (lactic-co-glycolic acid) (PLGA) nanoparticles (NPs).
- To compare the antimicrobial efficacy of VCM-loaded PLGA NPs with VCM solution against clinical Enterococcus isolates.
- To evaluate the effectiveness of VCM-loaded PLGA NPs against vancomycin-resistant Enterococcus.
Main Methods:
- VCM-loaded PLGA NPs were fabricated using the W1/O/W2 solvent evaporation method.
- Minimum Inhibitory Concentration (MIC) assays were performed to compare antimicrobial activity.
- Antimicrobial effects were tested against both vancomycin-susceptible and vancomycin-resistant clinical Enterococcus isolates.
Main Results:
- VCM-loaded PLGA NPs exhibited a significantly reduced antimicrobial effect compared to VCM solution.
- The efficacy of VCM-loaded NPs against vancomycin-resistant Enterococcus was lower than against susceptible isolates.
- Reduced in vitro antimicrobial activity may be due to slow VCM release from PLGA NPs caused by electrostatic interactions.
Conclusions:
- Vancomycin-loaded PLGA nanoparticles demonstrate diminished antimicrobial activity in vitro.
- The formulation may not be optimal for treating Enterococcus infections, particularly resistant strains.
- Further research is needed to optimize NP formulations for improved antibiotic delivery and efficacy.
Related Concept Videos
Antimicrobial Effectiveness
Clinical Significance of Antibiotic Resistance
Inhibitors of Gram-positive Cell Wall Synthesis

